Sharon E. Underberg sold $3.6M of IDXX
EVP, GC & Corporate Secretary at IDEXX LABORATORIES INC /DE. 5,450 shares at an average of $651.60, traded Aug 8, 2025, filed Aug 12, 2025.
Score components
- +15RoleOfficer
- +25Trade size$3.6M at market
- +10Share of holdings soldSold 47% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874716-25-000135, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | MOption exercise Common Stock | +5,450 | $206.94 | $1.1M | 11,606 | Aug 12, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stock | -5,450 | $651.60 | $3.6M | 6,156 | Aug 12, 2025 |
| Aug 12, 2025 | MOption exercise Common Stock | +183 | $544.08 | $100k | 6,339 | Aug 12, 2025 |
| Aug 8, 2025 | MOption exercise Non-Qualified Stock Option (right-to-buy)derivative | -5,450 | $0.00 | $0 | 0 | Aug 12, 2025 |
| Aug 12, 2025 | MOption exercise Incentive Stock Option (right-to-buy)derivative | -183 | $0.00 | $0 | 0 | Aug 12, 2025 |
Related signals
Other insiders at IDEXX LABORATORIES INC /DE and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | IDXXsell IDEXX LABORATORIES INC /DE | Lawrence D Kingsley director | $1.2M 2,203 shares | -19% | |
| 35Weak | IDXXsell IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $6.6M 9,425 shares | -31% | |
| 60Notable | IDEXX LABORATORIES INC /DE | M Anne Szostak director | $1.4M 2,187 shares | -89% | |
| 43Moderate | IDEXX LABORATORIES INC /DE | Michael G Erickson Executive Vice President | $264k 406 shares | -3% | |
| 37Weak | IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $788k 1,200 shares | -7% | |
| 50Moderate | IDEXX LABORATORIES INC /DE | Nimrata Hunt Executive Vice President | $4.5M 7,143 shares | -28% | |
| 60Notable | IDEXX LABORATORIES INC /DE | Michael Lane Executive Vice President | $5.3M 8,411 shares | -54% | |
| 60Notable | IDEXX LABORATORIES INC /DE | Jonathan Jay Mazelsky President and CEO | $18M 29,260 shares | -26% | |
| 60Notable | IDEXX LABORATORIES INC /DE | M Anne Szostak director | $1.2M 2,306 shares | -176% | |
| 50Moderate | IDEXX LABORATORIES INC /DE | Daniel M Junius director | $1.4M 2,683 shares | -45% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.